secwatch.observer — SEC 8-K summary
======================================

Issuer:     CervoMed Inc. (CRVO)
CIK:        0001053691
Form:       8-K
Filed at:   2023-07-31T23:59:59+00:00
Accession:  0001437749-23-021201
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Diffusion Pharmaceuticals appoints Jill Davidson to board under settlement agreement
--------------------------------------------------------------------------------

- Jill Davidson appointed as director effective July 26, 2023, expanding board to seven members.
- Appointment made pursuant to December 2022 Settlement Agreement with LifeSci Group.
- Davidson designated as one of two Company Designees for post-merger board if EIP Pharma merger closes.
- Term expires at 2023 annual meeting or when LifeSci Group's net long position falls below 96,976 shares.
- Davidson will receive standard non-employee director compensation and enter indemnification agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053691/000143774923021201/0001437749-23-021201-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053691/000143774923021201/dffn20230731_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-021201

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer